Trials / Withdrawn
WithdrawnNCT04456088
Inhaled NO for the Treatment of COVID-19 Caused by SARS-CoV-2 (CANADA Trial)
Inhaled NO for the Treatment of COVID-19 Caused by SARS-CoV-2
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Beyond Air Inc. · Industry
- Sex
- All
- Age
- 22 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this open label, 2-phase, study is to obtain information on the safety of 80 ppm and the safety and efficacy of 150 ppm Nitric Oxide given in addition to the standard of care of patients with COVID-19 caused by SARS-CoV-2.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| COMBINATION_PRODUCT | 150 ppm Nitric Oxide delivered through LungFit Delivery System | Nitric Oxide delivered via LungFit system. Patients will receive inhalations of 150 ppm for 40 minutes 4 time per day plus standard supportive care. |
| COMBINATION_PRODUCT | 80 ppm Nitric Oxide delivered through LungFit Delivery System | Nitric Oxide delivered via LungFit system. Patients will receive inhalations of 80 ppm for 40 minutes 4 time per day plus standard supportive care. |
Timeline
- Start date
- 2020-07-15
- Primary completion
- 2020-11-15
- Completion
- 2020-12-15
- First posted
- 2020-07-02
- Last updated
- 2021-01-22
Source: ClinicalTrials.gov record NCT04456088. Inclusion in this directory is not an endorsement.